Etoposide Induces Cell Death Via Mitochondrial-dependent Actions of P53

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2015 Aug 8

PMID 26251638

Citations 34

Authors

Sarwat Jamil

Irene Lam

Maryam Majd

Shu-Huei Tsai

Vincent Duronio

Affiliations

Soon will be listed here.

Abstract

Background: Etoposide has been used clinically in cancer treatment, as well as in numerous research studies, for many years. However, there is incomplete information about its exact mechanism of action in induction of cell death.

Methods: Etoposide was compared at various concentrations to characterize the mechanisms by which it induces cell death. We investigated its effects on mouse embryonic fibroblasts (MEFs) and focused on both transcriptional and non-transcriptional responses of p53.

Results: Here we demonstrate that treatment of MEFs with higher concentrations of etoposide induce apoptosis and activate the transcription-dependent functions of p53. Interestingly, lower concentrations of etoposide also induced apoptosis, but without any evidence of p53-dependent transcription up-regulation. Treatment of MEFs with an inhibitor of p53, Pifithrin-α, blocked p53-dependent transcription but failed to rescue the cells from etoposide-induced apoptosis. Treatment with PES, which inhibits the mitochondrial arm of the p53 pathway inhibited etoposide-induced cell death at all concentrations tested.

Conclusions: We have demonstrated that transcriptional functions of p53 are dispensable for etoposide-induced cell death. The more recently characterized effects of p53 at the mitochondria, likely involving its interactions with BCL-2 family members, are thus more important for etoposide's actions.

Citing Articles

Dysregulation of the p53 pathway provides a therapeutic target in aggressive pediatric sarcomas with stem-like traits.

Curylova L, Zambo I, Neradil J, Kyr M, Jurackova N, Pavlova S Cell Oncol (Dordr). 2024; 47(6):2317-2334.

PMID: 39630408 DOI: 10.1007/s13402-024-01020-x.

Exploring Senolytic and Senomorphic Properties of Medicinal Plants for Anti-Aging Therapies.

Imb M, Veghelyi Z, Maurer M, Kuhnel H Int J Mol Sci. 2024; 25(19).

PMID: 39408750 PMC: 11476546. DOI: 10.3390/ijms251910419.

Exploration of the link between COVID-19 and gastric cancer from the perspective of bioinformatics and systems biology.

Ma X, Huang T, Li X, Zhou X, Pan H, Du A Front Med (Lausanne). 2024; 11:1428973.

PMID: 39371335 PMC: 11449776. DOI: 10.3389/fmed.2024.1428973.

Potential Protective Effect of Hesperidin (Vitamin P) against Glyphosate-Induced Spermatogenesis Damage in Male Rats: Biochemical and Histopathological Findings on Reproductive Parameters.

Gungor S, Kirikkulak M, Denk B, Gulhan M, Gules O, Budak D Life (Basel). 2024; 14(9).

PMID: 39337973 PMC: 11433275. DOI: 10.3390/life14091190.

An Overview of Altered Pathways Associated with Sensitivity to Platinum-Based Chemotherapy in Neuroendocrine Tumors: Strengths and Prospects.

Stefano E, Castro F, Ciccarese A, Muscella A, Marsigliante S, Benedetti M Int J Mol Sci. 2024; 25(16).

PMID: 39201255 PMC: 11354135. DOI: 10.3390/ijms25168568.

References

Gudkov A, Komarova E . Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet. 2007; 16 Spec No 1:R67-72. DOI: 10.1093/hmg/ddm052. View

Miyashita T, Harigai M, Hanada M, Reed J . Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994; 54(12):3131-5. View

Burden D, Kingma P, Froelich-Ammon S, Bjornsti M, Patchan M, Thompson R . Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem. 1996; 271(46):29238-44. DOI: 10.1074/jbc.271.46.29238. View

Sohn D, Graupner V, Neise D, Essmann F, Schulze-Osthoff K, Janicke R . Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53. Cell Death Differ. 2009; 16(6):869-78. DOI: 10.1038/cdd.2009.17. View

Wolff S, Erster S, Palacios G, Moll U . p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res. 2008; 18(7):733-44. PMC: 2830652. DOI: 10.1038/cr.2008.62. View

Ito A, Lai C, Zhao X, Saito S, Hamilton M, Appella E . p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001; 20(6):1331-40. PMC: 145533. DOI: 10.1093/emboj/20.6.1331. View

Haldar S, Negrini M, Monne M, Sabbioni S, Croce C . Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994; 54(8):2095-7. View

Komarov P, Komarova E, Kondratov R, Coon J, Chernov M, Gudkov A . A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285(5434):1733-7. DOI: 10.1126/science.285.5434.1733. View

Speidel D, Helmbold H, Deppert W . Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress. Oncogene. 2005; 25(6):940-53. DOI: 10.1038/sj.onc.1209126. View

10.

Unger T, Juven-Gershon T, Moallem E, Berger M, Sionov R, Lozano G . Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 1999; 18(7):1805-14. PMC: 1171266. DOI: 10.1093/emboj/18.7.1805. View

11.

Johnson T, Meade K, Pathak N, Marques M, Attardi L . Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc Natl Acad Sci U S A. 2008; 105(4):1215-20. PMC: 2234118. DOI: 10.1073/pnas.0706764105. View

12.

Balaburski G, Leu J, Beeharry N, Hayik S, Andrake M, Zhang G . A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res. 2013; 11(3):219-29. PMC: 3606282. DOI: 10.1158/1541-7786.MCR-12-0547-T. View

13.

Kobet E, Zeng X, Zhu Y, Keller D, Lu H . MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci U S A. 2000; 97(23):12547-52. PMC: 18801. DOI: 10.1073/pnas.97.23.12547. View

14.

Vaseva A, Moll U . The mitochondrial p53 pathway. Biochim Biophys Acta. 2008; 1787(5):414-20. PMC: 2819081. DOI: 10.1016/j.bbabio.2008.10.005. View

15.

Nigg E . Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001; 2(1):21-32. DOI: 10.1038/35048096. View

16.

Miyashita T, Krajewski S, Krajewska M, Wang H, Lin H, Liebermann D . Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994; 9(6):1799-805. View

17.

Leu J, Dumont P, Hafey M, Murphy M, George D . Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol. 2004; 6(5):443-50. DOI: 10.1038/ncb1123. View

18.

Minami H, Ando Y, Sakai S, Shimokata K . Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol. 1995; 13(1):191-9. DOI: 10.1200/JCO.1995.13.1.191. View

19.

Ito A, Kawaguchi Y, Lai C, Kovacs J, Higashimoto Y, Appella E . MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002; 21(22):6236-45. PMC: 137207. DOI: 10.1093/emboj/cdf616. View

20.

Appella E, Anderson C . Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem. 2001; 268(10):2764-72. DOI: 10.1046/j.1432-1327.2001.02225.x. View